Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype

1. Yasar Ü , Eliasson E , Dahl M-L , Johansson I , Ingelman-Sundberg M , Sjöqvist F . Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628–31. Erratum 1999; 258: 227.

2. Daly AK , King BP . Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247–52.

3. Yasar Ü , Dahl M-L , Christensen M , Eliasson E . Intra-individual variability in urinary losartan oxidation ratio, an in vivo-marker of CYP2C9 activity. Br J Clin Pharmacol 2002; 54: 183–5.

4. Verstuyft C , Robert A , Morin S , Loriot MA , Flahault A , Beaune P , Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol 2003; 58: 739–45.

5. Takahashi H , Wilkinson GR , Caraco Y , Muszkat M , Kim RB , Kashima T , Population differences in S-warfarin metabolism between CYP2C9 genotype—matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253–63.